Login to Your Account

After Avanir and Jazz Pharma

All in 'Deuterium': Concert Play Maturing, Draws Celgene Deal

By Randy Osborne
Staff Writer

Tuesday, May 7, 2013
Concert Pharmaceuticals Inc.'s third deal in just over two years with its deuterium-modifying platform brought Celgene Corp. aboard for a single project at first – an up-front payment along with more than $300 million possible in milestone rewards – but with the potential for more compounds that would bring similar financial terms.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription